NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting ‌on a ​new wave of ...

Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...

Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how ...

Johnon & Johnson said late Thursday it will lower prices for certain prescription drugs and match the rates in other ...

The Schwab U.S. Dividend Equity ETF remains an excellent choice for income-seeking investors, even net of its recent ...

Poplar Therapeutics Inc. launched on Wednesday capitalized with $50 million Series A financing and led by Chip Baird, the ...

A federal appeals court on Wednesday blocked a Trump administration plan to require hospitals serving low-income Americans to ...

Fintel reports that on January 7, 2026, UBS upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy.

Fintel reports that on January 7, 2026, UBS upgraded their outlook for Bristol-Myers Squibb Company - Preferred Security (OTCPK:BMYMP) from Neutral to Buy. Analyst Price Forecast Suggests 25.45% ...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

Gilead Sciences promoted Keeley Wettan to EVP, general counsel, legal and compliance. She will join the senior leadership ...